| scholarly article | Q13442814 |
| P356 | DOI | 10.18632/ONCOTARGET.1687 |
| P8608 | Fatcat ID | release_6nsd3isebzahneej7pc6shuqn4 |
| P932 | PMC publication ID | 4102787 |
| P698 | PubMed publication ID | 24931142 |
| P5875 | ResearchGate publication ID | 263131224 |
| P50 | author | Razelle Kurzrock | Q56614941 |
| Apostolia Maria Tsimberidou | Q56761627 | ||
| Filip Janku | Q73569186 | ||
| P2093 | author name string | Robert A Wolff | |
| Ahmed O Kaseb | |||
| P2860 | cites work | BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization | Q24337105 |
| Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma | Q24606279 | ||
| COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer | Q24608391 | ||
| ARID1A mutations in endometriosis-associated ovarian carcinomas | Q24610484 | ||
| FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis | Q24617480 | ||
| Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia | Q24680303 | ||
| Targeted therapy for hepatocellular carcinoma: novel agents on the horizon | Q27002288 | ||
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer | Q27851588 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| Elucidating distinct roles for NF1 in melanomagenesis | Q27851952 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers | Q28115840 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors | Q28144693 | ||
| Hot spots in beta-catenin for interactions with LEF-1, conductin and APC | Q28145062 | ||
| Neurofibromatosis type 1 - a model for nervous system tumour formation? | Q28265284 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| FGF4, a direct target of LEF1 and Wnt signaling, can rescue the arrest of tooth organogenesis in Lef1(-/-) mice | Q28505123 | ||
| ATM and related protein kinases: safeguarding genome integrity | Q29547735 | ||
| Hepatocellular carcinoma | Q29615765 | ||
| Hyperactive Ras in developmental disorders and cancer | Q29616397 | ||
| High-resolution characterization of a hepatocellular carcinoma genome | Q31005512 | ||
| An alternative splicing network links cell-cycle control to apoptosis | Q34077168 | ||
| Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer | Q34101115 | ||
| mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cells | Q34360637 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| Elevated expression of CDK4 in lung cancer | Q34980269 | ||
| Activating mutations of TOR (target of rapamycin). | Q35049778 | ||
| Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis | Q35168290 | ||
| Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines | Q35212640 | ||
| Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs | Q35640098 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Will PI3K pathway inhibitors be effective as single agents in patients with cancer? | Q35764392 | ||
| Aberrant and alternative splicing in cancer | Q35936123 | ||
| Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: Evidence from a systematic review and meta-analysis | Q36092123 | ||
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma | Q36160273 | ||
| PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials | Q36510935 | ||
| Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine | Q36984831 | ||
| mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. | Q36987718 | ||
| Structural biology of the tumor suppressor p53. | Q37137883 | ||
| Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
| The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy | Q37299276 | ||
| Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. | Q37480094 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma | Q38042261 | ||
| Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. | Q39582682 | ||
| Analysis of canonical and non-canonical splice sites in mammalian genomes | Q39597422 | ||
| Exploiting the homologous recombination DNA repair network for targeted cancer therapy | Q39747596 | ||
| The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Q40399567 | ||
| The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer | Q43127413 | ||
| Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis | Q44503107 | ||
| A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma | Q45310295 | ||
| Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor) | Q73270781 | ||
| p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors | Q74292661 | ||
| Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm | Q77316447 | ||
| Amplification of c-myc and cyclin D1 genes in primary and metastatic carcinomas of the liver | Q80516916 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 3012-3022 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing | |
| P478 | volume | 5 |
| Q38430715 | A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma. |
| Q38949674 | Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation |
| Q47226208 | Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis |
| Q27006707 | Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives |
| Q58804958 | Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway |
| Q37086000 | Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma |
| Q36946723 | CTNNA3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425 |
| Q36849642 | Changing paradigm of cancer therapy: precision medicine by next-generation sequencing |
| Q28077738 | Combination treatment including targeted therapy for advanced hepatocellular carcinoma |
| Q36895507 | Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients |
| Q46525101 | Dramatic Response to Carboplatin, Paclitaxel, and Radiation in a Patient With Malignant Myoepithelioma of the Breast |
| Q42027870 | Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma |
| Q36167088 | Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer |
| Q37631655 | From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers |
| Q28073241 | Genetic alterations in hepatocellular carcinoma: An update |
| Q38825761 | Glucose-regulated protein 94 mediates cancer progression via AKT and eNOS in hepatocellular carcinoma |
| Q92876631 | Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies |
| Q45943794 | Identifying and analyzing different cancer subtypes using RNA-seq data of blood platelets. |
| Q47216499 | Inducible T-cell co-stimulators regulate the proliferation and invasion of human hepatocellular carcinoma HepG2 cells |
| Q36640592 | Long non-coding RNA HOTAIR is a marker for hepatocellular carcinoma progression and tumor recurrence |
| Q30252143 | Management strategies for hepatocellular carcinoma: old certainties and new realities. |
| Q58693431 | Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma |
| Q64236080 | Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma |
| Q34619203 | Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. |
| Q35833018 | PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. |
| Q47570425 | Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function |
| Q38936589 | Promising new strategies for hepatocellular carcinoma |
| Q34628699 | Sevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signaling |
| Q38726203 | TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication |
| Q64054403 | Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression |
| Q38635474 | The biology of Hepatocellular carcinoma: implications for genomic and immune therapies |
| Q38629203 | The changing landscape of phase I trials in oncology |
| Q52363678 | The crucial role of multiomic approach in cancer research and clinically relevant outcomes. |
| Q38871688 | The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells |
| Q26743361 | Tissue- and Serum-Associated Biomarkers of Hepatocellular Carcinoma |
| Q36562222 | Whole transcriptome sequencing identifies BCOR internal tandem duplication as a common feature of clear cell sarcoma of the kidney |
| Q38815508 | miR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway |
Search more.